Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)

Publisher Name :
Date: 01-Aug-2018
No. of pages: 101

Scope of the Report

The report titled “Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)”, provides an in depth analysis of the global PD-1 and PD-L1 inhibitors market by value, by cancer, by treatment, by region, etc. The report also provides a detailed analysis of the China PD-1 and PD-L1 inhibitors market by value, by treatment and by cancer.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global PD-1 and PD-L1 Inhibitors market has also been forecasted for the period 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global PD-1 and PD-L1 inhibitors market is generally dominated. Many competitors have established worldwide reputation with the multinational patients while some provide their drugs to the domestic patients. The manufacturers of the PD-1 and PD-1 inhibitors market produce different type of drugs, some manufacturers produce PD-1 inhibitors, some produce PD-L1 inhibitors while other produce combination of PD-1 and PD-L1 inhibitors.

However, the competition in the global PD-1 and PD-L1 inhibitors market is dominated by few PD-1 and PD-L1 inhibitors manufacturers. Further, key players of the PD-1 and PD-L1 inhibitors market are Bristol-Myers Squibb, Merck & Co., Inc., Roche, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd. and BeiGene, Ltd. are also profiled with their financial information and respective business strategies.

Country Coverage


  • China

  • The US

  • ROW


Company Coverage


  • Bristol-Myers Squibb

  • Merck & Co., Inc.

  • Roche

  • AstraZeneca

  • Jiangsu Hengrui Medicine Co. Ltd.

  • BeiGene, Ltd.


Executive Summary

Cancer is the fastest growing disease across the world and one of the most important development in the field of cancer treatment is the introduction of immune checkpoint inhibitors-agents that help to stimulate the immune system. The two main cancer treatment approaches are: Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) inhibitors. PD-1 and PD-L1 inhibitors are both found on the surface of the cancer cells and used to kill cancer cells.

The drugs approved as a PD-1 inhibitor are Pembrolizumab and Nivolumab and the drugs approved as a PD-L1 inhibitors are atezolizumab, Durvalumab and Avelumab. There are various PD-1 and PD-L1 inhibitors which are still in experimental phase of development. The adverse effects of PD-1 and PD-L1 inhibitors are pneumonitis, colitis, skin reactions, immune thrombocytopenia, cardiac insufficiency, diarrhea, pruritus, myocarditis and pneumonitis. PD-1 and PD-L1 inhibitors has a long history with continuously evolving new generation PD-1 and PD-L1 inhibitors. The PD-1 and PD-L1 inhibitors market can be segmented on the basis of type, indications, drug and distribution channel.

The global PD-1 and PD-L1 inhibitors market has increased at a significant annual growth rate during the years 2016-2017 and projections are made that the market would rise in the next four years i.e. 2018-2022 tremendously. The PD-1 and PD-L1 inhibitors market is expected to increase due to aging population, growth in GNI per capita, growing urban population, increasing incidence of certain types of cancer, rise in the number of people with cancer, etc. Yet the market faces some challenges such as high cost of oncology treatment, side effects and toxicity, failure of clinical trials, time consuming and uncertain regulatory process, etc.

Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)

Table of Contents

1. Executive Summary

2. Introduction
2.1 PD-1 and PD-L1 Inhibitors: An Overview
2.1.1 PD-1 and PD-L1 Inhibitors Discovery Timeline
2.1.2 PD-1/PD-L1 Inhibitors Mechanism Action and Applications
2.1.3 PD-1/PD-L1 Inhibitors in Experimental Phase of Development
2.1.4 Adverse Effects of PD-1 and PD-L1 Inhibitors
2.2 PD-1 and PD-L1 Inhibitors Segmentation: An Overview
2.2.1 PD-1 and PD-L1 Inhibitors by Type
2.2.2 PD-1 and PD-L1 Inhibitors by Indications
2.2.3 PD-1 and PD-L1 Inhibitors by Drug
2.2.4 PD-1 and PD-L1 Inhibitors by Distribution Channel

3. Global Market Analysis
3.1 Global PD-1 and PD-L1 Inhibitors Market: An Analysis
3.1.1 Global PD-1 and PD-L1 Inhibitors Market by Value
3.1.2 Global PD-1 and PD-L1 Inhibitors Market by Segments (Metastatic PD-1 and PD-L1 Inhibitors and Adjuvant PD-1 and PD-L1 Inhibitors)
3.1.3 Global PD-1 and PD-L1 Inhibitors Market by Region (The US, China and ROW)
3.2 Global PD-1 and PD-L1 Inhibitors Market: Segment Analysis
3.2.1 Global Metastatic PD-1 and PD-L1 Inhibitors Market by Value
3.2.2 Global Adjuvant PD-1 and PD-L1 Inhibitors Market by Value

4. Regional Market Analysis
4.1 China PD-1 and PD-L1 Inhibitors Market: An Analysis
4.1.1 China PD-1 and PD-L1 Inhibitors Market by Value
4.1.2 China PD-1 and PD-L1 Inhibitors Market by Cancer (Non-small Cell Lung Carcinoma, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Small Cell Lung Cancer and Others)
4.1.3 China PD-1 and PD-L1 Inhibitors Market by Treatment (1L Treatment and 2L+ Treatment)
4.2 China PD-1 and PD-L1 Inhibitors Market: Treatment Analysis
4.2.1 China 1L PD-1 and PD-L1 Inhibitors Market by Value
4.2.2 China 1L PD-1 and PD-L1 Inhibitors Market by Cancer (Non-small Cell Lung Carcinoma, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Small Cell Lung Cancer and Others)
4.2.3 China 2L+ PD-1 and PD-L1 Inhibitors Market by Value
4.2.4 China 2L+ PD-1 and PD-L1 Inhibitors Market by Cancer (Non-small Cell Lung Carcinoma, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Cancer, Small Cell Lung Cancer and Others)
4.3 China PD-1 and PD-L1 Inhibitors Market: Cancer Analysis
4.3.1 China Non-small Cell Lung Cancer (NSCLC) Market by Value
4.3.2 China Non-small Cell Lung Cancer (NSCLC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.3 China 1L and 2L+ Non-small Cell Lung Cancer (NSCLC) Treatment Market by Value
4.3.4 China Small Cell Lung Cancer (SCLC) Market by Value
4.3.5 China Small Cell Lung Cancer (SCLC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.6 China 1L and 2L+ Small Cell Lung Cancer (SCLC) Treatment Market by Value
4.3.7 China Hepatocellular Carcinoma (HCC) Market by Value
4.3.8 China Hepatocellular Carcinoma (HCC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.9 China 1L and 2L+ Hepatocellular Carcinoma (HCC) Treatment Market by Value
4.3.10 China Gastric Cancer (GC) Market by Value
4.3.11 China Gastric Cancer (GC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.12 China 1L and 2L+ Gastric Cancer (GC) Treatment Market by Value
4.3.13 China Esophageal Squamous Cell Carcinoma (ESCC) Market by Value
4.3.14 China Esophageal Squamous Cell Carcinoma (ESCC) Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.15 China 1L and 2L+ Esophageal Squamous Cell Carcinoma (ESCC) Treatment Market by Value
4.3.16 China Other Cancers Market by Value
4.3.17 China Other Cancers Market by Treatment (1L Treatment and 2L+ Treatment)
4.3.18 China 1L and 2L+ Other Cancers Treatment Market by Value
4.4 The US PD-1 and PD-L1 Inhibitors Market: An Analysis
4.4.1 The US PD-1 and PD-L1 Inhibitors Market by Value
4.5 ROW PD-1 and PD-L1 Inhibitors Market: An Analysis
4.5.1 ROW PD-1 and PD-L1 Inhibitors Market by Value

5. Market Dynamics
5.1 Growth Driver
5.1.1 Aging Population
5.1.2 Increasing GNI Per Capita
5.1.3 Growing Urban Population
5.1.4 Increased Incidence of Certain Types of Cancer
5.1.5 Surge in the Number of People with Cancer by Age
5.2 Challenges
5.2.1 High Cost of Oncology Treatment
5.2.2 Side Effects and Toxicity
5.2.3 Failure of Clinical Trial
5.2.4 Time Consuming and Uncertain Regulatory Process
5.3 Market Trends
5.3.1 Rising Healthcare Awareness and Changing Lifestyle
5.3.2 Public Medical Insurance
5.3.3 Accelerated Approval of New PD-1 and PD-L1 Inhibitors
5.3.4 Increased Consumption of Alcohol and Smoking

6. Competitive Landscape
6.1 Global PD-1 and PD-L1 Inhibitors Market: Competitive Landscape
6.2 Global PD-1 and PD-L1 Inhibitors Market Players by Phase 3 Studies
6.3 Regulatory Status of Key PD-L1 Drugs in China

7. Company Profiles
7.1 Bristol-Myers Squibb
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 Merck & Co., Inc.
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Roche
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 AstraZeneca
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
7.5 Jiangsu Hengrui Medicine Co. Ltd.
7.6 BeiGene, Ltd.

List of Tables

Table 1: PD-1/PD-L1 Inhibitors Mechanism Action and Applications
Table 2: Approved PD-1 and PD-L1 inhibitors Timeline; 2017
Table 3: Global PD-1 and PD-L1 Inhibitors Market: Competitive Landscape
Table 4: Regulatory Status of Key PD-L1 Drugs in China

List of Figures

1: PD-1 and PD-L1 Inhibitors Discovery Timeline
Figure 2: PD-1/PD-L1 Inhibitors in Experimental Phase of Development
Figure 3: Adverse Effects of PD-1 and PD-L1 Inhibitors
Figure 4: PD-1 and PD-L1 Inhibitors by Type
Figure 5: PD-1 and PD-L1 Inhibitors by Indications
Figure 6: PD-1 and PD-L1 Inhibitors by Drug
Figure 7: PD-1 and PD-L1 Inhibitors by Distribution Channel
Figure 8: Global PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Figure 9: Global PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 10: Global PD-1 and PD-L1 Inhibitors Market by Segments; 2017 (Percentage, %)
Figure 11: Global PD-1 and PD-L1 Inhibitors Market by Region; 2017-2018 (Percentage, %)
Figure 12: Global Metastatic PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Figure 13: Global Metastatic PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 14: Global Adjuvant PD-1 and PD-L1 Inhibitors Market by Value; 2017-2022 (US$ Billion)
Figure 15: China PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 16: China PD-1 and PD-L1 Inhibitors Market by Cancer; 2018 & 2022 (Percentage, %)
Figure 17: China PD-1 and PD-L1 Inhibitors Market by Treatment; 2018 (Percentage, %)
Figure 18: China 1L PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 19: China 1L PD-1 and PD-L1 Inhibitors Market by Cancer; 2018 (Percentage, %)
Figure 20: China 2L+ PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Million)
Figure 21: China 2L+ PD-1 and PD-L1 Inhibitors Market by Cancer; 2018 (Percentage, %)
Figure 22: China Non-small Cell Lung Cancer (NSCLC) Market by Value; 2018-2022 (US$ Billion)
Figure 23: China Non-small Cell Lung Cancer (NSCLC) Market by Treatment; 2018 (Percentage, %)
Figure 24: China 1L Non-small Cell Lung Cancer (NSCLC) Treatment Market by Value; 2018-2022 US$ Billion)
Figure 25: China 2L+ Non-small Cell Lung Cancer (NSCLC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 26: China Small Cell Lung Cancer (SCLC) Market by Value; 2018-2022 (US$ Million)
Figure 27: China Small Cell Lung Cancer (SCLC) Market by Treatment; 2018 (Percentage, %)
Figure 28: China 1L Small Cell Lung Cancer (SCLC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 29: China 2L+ Small Cell Lung Cancer (SCLC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 30: China Hepatocellular Carcinoma (HCC) Market by Value; 2018-2022 (US$ Million)
Figure 31: China Hepatocellular Carcinoma (HCC) Market by Treatment; 2018 (Percentage, %)
Figure 32: China 1L Hepatocellular Carcinoma (HCC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 33: China 2L+ Hepatocellular Carcinoma (HCC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 34: China Gastric Cancer (GC) Market by Value; 2018-2022 (US$ Million)
Figure 35: China Gastric Cancer (GC) Market by Treatment; 2018 (Percentage, %)
Figure 36: China 1L Gastric Cancer (GC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 37: China 2L+ Gastric Cancer (GC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 38: China Esophageal Squamous Cell Carcinoma (ESCC) Market by Value; 2018-2022 (US$ Million)
Figure 39: China Esophageal Squamous Cell Carcinoma (ESCC) Market by Treatment; 2018 (Percentage, %)
Figure 40: China 1L Esophageal Squamous Cell Carcinoma (ESCC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 41: China 2L+ Esophageal Squamous Cell Carcinoma (ESCC) Treatment Market by Value; 2018-2022 (US$ Million)
Figure 42: China Other Cancers Market by Value; 2018-2022 (US$ Million)
Figure 43: China Other Cancers Market by Treatment; 2018 (Percentage, %)
Figure 44: China 1L Other Cancers Treatment Market by Value; 2018-2022 (US$ Million)
Figure 45: China 2L+ Other Cancers Treatment Market by Value; 2018-2022 (US$ Million)
Figure 46: The US PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Figure 47: The US PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 48: ROW PD-1 and PD-L1 Inhibitors Market by Value; 2016-2017 (US$ Billion)
Figure 49: ROW PD-1 and PD-L1 Inhibitors Market by Value; 2018-2022 (US$ Billion)
Figure 50: World Aging Population by Gender ; 2011-2017 (Trillion)
Figure 51: Global GNI Per Capita; 2010-2016 (US$)
Figure 52: Global Urban Population; 2011-2017 (Billion)
Figure 53: Incidence of Certain Types of Cancer; 2017
Figure 54: Number of People with Cancer by Age; 2011-2016 (Million)
Figure 55: Global Oncology Treatment Cost; 2012-2016 (US$ Billion)
Figure 56: Global PD-1 and PD-L1 Inhibitors Market Players by Phase 3 Studies; 2017 (Percentage, %)
Figure 57: Bristol-Myers Squibb Total Revenue; 2013-2017 (US$ Billion)
Figure 58: Bristol-Myers Squibb Total Revenue by Products; 2017 (Percentage, %)
Figure 59: Bristol-Myers Squibb Total Revenue by Region; 2017 (Percentage, %)
Figure 60: Merck & Co. Inc. Sales; 2013-2017 (US$ Billion)
Figure 61: Merck & Co. Inc. Sales by Segment; 2017 (Percentage, %)
Figure 62: Merck & Co. Inc. Sales by Region; 2017 (Percentage, %)
Figure 63: Roche Sales; 2013-2017 (US$ Billion)
Figure 64: Roche Sales by Segments; 2017 (Percentage,%)
Figure 65: Roche Sales by Region; 2017 (Percentage, %)
Figure 66: AstraZeneca Total Revenue; 2013-2017 (US$ Billion)
Figure 67: AstraZeneca Total Revenue by Region; 2017 (Percentage, %)

  • 2018-2023 Global Probiotics Gummies Consumption Market Report
    Published: 16-Aug-2018        Price: US 4660 Onwards        Pages: 167
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Probiotics Gummies market for 2018-2023. In the humble human gut, there are hundreds of trillions of bacterial occupants, and they're not just living there — they're working for you. Gut flora makes up 70-80 percent of the human immune system. Adding good bacteria, called probiotics, protects the digestive tract from the harmful bacteria in sugars, pesticid......
  • Global Tuberculosis Diagnostics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Aug-2018        Price: US 3480 Onwards        Pages: 136
    Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Tuberculosis Diagnostics Market 2018, Forecast to 2023
    Published: 16-Aug-2018        Price: US 4880 Onwards        Pages: 132
    Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night......
  • Global Human Rabies Immunoglobulin (IM) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Aug-2018        Price: US 3480 Onwards        Pages: 129
    Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure. Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches ......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Human Rabies Immunoglobulin (IM) Market 2018, Forecast to 2023
    Published: 16-Aug-2018        Price: US 4880 Onwards        Pages: 133
    Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure. Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches ......
  • Global Recombinant Trypsin Solution Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Aug-2018        Price: US 3480 Onwards        Pages: 137
    Recombinant Trypsin is a genetically engineered protein expressed in E-Coli. As such it is totally animal free, free from contaminating enzymes like chymotrysin as well as protease inhibitors. It is highly stable with a high purity. It is widely used in insulin manufacturing, Vaccines Manufacturing and cell culture applications. Scope of the Report: This report focuses on the Recombinant Trypsin Solution in global market, especially in North America, Europe and Asia-Pacific......
  • 2018-2023 Global Milk Allergy Clinical Trials Review Consumption Market Report
    Published: 16-Aug-2018        Price: US 4660 Onwards        Pages: 133
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Milk Allergy Clinical Trials Review market for 2018-2023. Cow's milk allergy (CMA) is among the most common FA in early childhood, with an estimated prevalence of 2% to 3%. The mission for Milk Allergy Clinical Trials is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases. Over......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Recombinant Trypsin Solution Market 2018, Forecast to 2023
    Published: 16-Aug-2018        Price: US 4880 Onwards        Pages: 129
    Recombinant Trypsin is a genetically engineered protein expressed in E-Coli. As such it is totally animal free, free from contaminating enzymes like chymotrysin as well as protease inhibitors. It is highly stable with a high purity. It is widely used in insulin manufacturing, Vaccines Manufacturing and cell culture applications. Scope of the Report: This report focuses on the Recombinant Trypsin Solution in global market, especially in North America, Europe and Asia-Pacific......
  • 2018-2023 Global Dementia Drugs Consumption Market Report
    Published: 16-Aug-2018        Price: US 4660 Onwards        Pages: 158
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Dementia Drugs market for 2018-2023. Over the next five years, LPI(LP Information) projects that Dementia Drugs will register a 8.5% CAGR in terms of revenue, reach US$ 22700 million by 2023, from US$ 13900 million in 2017. This report presents a comprehensive overview, market shares, and growth opportunities of Dementia Drugs market by produ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs